Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Switch to Second-line Versus WHO-guided Standard of Care for Unsuppressed Patients on First-line ART With Viremia Below 1000 Copies/mL - a Multicenter, Parallel-group, Open-label, Randomized Clinical Study in Rural Lesotho

NCT03088241 is registered in ClinicalTrials.gov with Niklaus Labhardt as lead sponsor.

NCT NCT03088241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03088241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Switch to Second-line Versus WHO-guided Standard of Care for Unsuppressed Patients on First-line ART With Viremia Below 1000 Copies/mL - a Multicenter, Parallel-group, Open-label, Randomized Clinical Study in Rural Lesotho
Lead sponsor
Niklaus Labhardt
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2017
Completion date
May 23, 2020
Enrollment
80 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

hiv/aids